KOSDAQBiotech & Pharma330350

Withus Pharmaceutical

₩6,410▲ 0.94%2026-11-18 close
Market Cap
₩84.6B
Turnover
₩100M
Volume
20K
Shares out.
13.2M
PER
11.9×
PBR
0.8×
EPS
₩537
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Revenue Grows, Margins Narrow at Withus Pharmaceutical

Withus Pharmaceutical lifted revenue to KRW 106.4 billion in 2025, but its operating margin fell from 9.9% in 2023 to 5.3% in 2025. Revenue has risen for three straight quarters through the third quarter of 2026, while attributable net income has declined for two straight quarters.

  1. 1

    Revenue has risen for three consecutive years from 2023 through 2025, reaching KRW 106.4 billion in 2025. The 2025 growth rate of 3.6% was far below the 28.2% recorded in 2024.

  2. 2

    Operating margin fell from 9.9% in 2023 to 5.5% in 2024 and 5.3% in 2025. The company attributed the 2024 profitability decline to higher R&D and cost of sales, along with costs tied to its business restructuring.

  3. 3

    Third-quarter 2026 revenue rose 13.3% year on year to KRW 30.9 billion, while attributable net income fell 40.8% year on year to KRW 1.27 billion.

  4. 4

    On improved new drugs, a hypertension combination product received approval in February 2026 and launched in July, while two diabetes candidates were discontinued before clinical entry.

  5. 5

    Tablet manufacturing was suspended for one month from January 2026, and production resumed on February 20, 2026. The Anseong long-acting injectable plant has been cited as a production base for hair-loss drug developers.

02

Business structure

Withus Pharmaceutical, founded in 2005, is a finished-drug manufacturer focused on chronic-disease medicines in cardiovascular, musculoskeletal, digestive and antibiotic categories.

In 2022, cardiovascular products generated KRW 18.1 billion, musculoskeletal KRW 6.2 billion, digestive KRW 8.3 billion and antibiotics KRW 5.0 billion, against total revenue of KRW 64.7 billion for that year. Antibiotic sales rose to KRW 14.9 billion in 2023, with seasonal disease demand cited as a driver.

The company pursued bioequivalence testing to add its own products and limit the impact of price cuts, and since 2022 it has moved some products to contract sales organizations (CSO) to widen distribution. Its portfolio includes finasteride and dutasteride, the two ingredients that split the hair-loss drug market.

The core manufacturing asset is a dedicated plant in Anseong, built with about KRW 27.0 billion of investment in 2023 for long-acting injectables. In January 2026, tablet manufacturing was suspended for one month; a press calculation put the affected category at 81.71% of annual sales.

Production resumed on February 20, 2026. Reports describe Chong Kun Dang and Daewoong Pharmaceutical, both developing hair-loss treatments, as having chosen the company as a production partner. Competition comes from domestic generic and improved-new-drug makers.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩27.3B₩1.4B5.0%
2025Q4₩27.2B₩1.4B5.1%
2026Q1₩28.2B₩200M0.9%
2026Q2₩29.1B₩1.1B3.7%
2026Q3₩30.9B₩1.4B4.6%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩64.7B₩4.9B₩2.5B7.5%3.0%43.8%
2023₩80.1B₩7.9B₩8B9.9%8.8%44.9%
2024₩102.7B₩5.7B₩4.8B5.5%5.1%44.6%
2025₩106.4B₩5.7B₩5B5.3%5.1%39.4%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

Annual results show revenue and profit moving in different directions. Revenue rose from KRW 64.7 billion in 2022 to KRW 80.1 billion in 2023 (up 23.9%), KRW 102.7 billion in 2024 (up 28.2%) and KRW 106.4 billion in 2025 (up 3.6%).

Revenue has increased for three consecutive years from 2023 through 2025, and 2025 was the largest year of 2022 to 2025. Operating profit rose from KRW 4.88 billion in 2022 to KRW 7.91 billion in 2023 (up 62.2%), then fell to KRW 5.66 billion in 2024 (down 28.4%) and was flat at KRW 5.66 billion in 2025.

Operating margin was 7.5% in 2022, 9.9% in 2023, 5.5% in 2024 and 5.3% in 2025, so revenue growth after 2023 did not carry through to margins. For 2024, the company cited higher R&D and cost of sales, along with costs from its business restructuring.

Attributable net income was KRW 2.48 billion in 2022, KRW 7.96 billion in 2023 (up 221.0%), KRW 4.78 billion in 2024 (down 39.9%) and KRW 4.97 billion in 2025 (up 3.8%). Operating cash flow was KRW 5.38 billion in 2022, negative KRW 1.24 billion in 2023, KRW 9.63 billion in 2024 and KRW 6.78 billion in 2025.

The debt ratio was 39.4% at the end of 2025, the lowest of the four years, with total liabilities of KRW 38.6 billion and total equity of KRW 98 billion.

On a quarterly basis, revenue went from KRW 27.3 billion in the third quarter of 2025 to KRW 27.2 billion in the fourth quarter (down 0.3% quarter on quarter), then KRW 28.2 billion, KRW 29.1 billion and KRW 30.9 billion through the third quarter of 2026, which was up 13.3% year on year.

Operating profit bottomed at KRW 244 million in the first quarter of 2026 (down 82.3% quarter on quarter) and recovered to KRW 1.08 billion in the second quarter and KRW 1.41 billion in the third quarter, which was up 2.5% year on year.

Attributable net income was KRW 2.14 billion in the third quarter of 2025, a net loss of KRW 120 million in the fourth quarter (a turn to loss), KRW 3.97 billion in the first quarter of 2026 (a turn to profit), KRW 1.97 billion in the second quarter and KRW 1.27 billion in the third quarter.

The gap in the first quarter of 2026 between KRW 244 million of operating profit and KRW 3.97 billion of attributable net income points to non-operating or tax items, which the quarterly report's income lines should confirm.

The four quarters from the fourth quarter of 2025 through the third quarter of 2026 sum to KRW 7.09 billion of attributable net income.

05

Industry analysis

The hair-loss treatment market is split between finasteride and dutasteride, the two ingredients Withus Pharmaceutical has secured in its lineup. The company is positioning long-acting injectables, which change the dosing pattern, as its next growth engine.

These formulations release the drug ingredient slowly in the body so that a single administration maintains effect for a set period. As more domestic developers pursue this segment, securing manufacturing partners is becoming a central challenge for them.

The company has shifted its business mix by expanding its own products through bioequivalence testing, which it says limits exposure to price cuts.

In improved new drugs, results diverge by therapeutic area: a hypertension combination product reached the market, while two diabetes candidates were stopped before clinical entry. Chronic and age-related disease medicines are areas where demand is expected to persist as populations age.

Policy debate over reimbursement for hair-loss drugs and general drug pricing policy remain key variables for the sector.

Relative to larger listed biopharma peers such as Samsung Biologics and Celltrion, which focus on expanding biologics capacity, Withus Pharmaceutical is concentrated in oral drugs and long-acting injectables at a much smaller scale.

06

Outlook

The company has said that long-acting hair-loss injectables alone could add more than KRW 100 billion in revenue, but 2025 revenue grew only 3.6% year on year. That gap shows how long launches and approvals take to reach reported results.

Reports expected the Anseong injectable plant to obtain GMP certification in the first half of 2026, and whether that has been completed should be checked against the company's disclosures.

The hypertension combination product launched in July 2026, so how much it contributes to quarterly revenue is the next checkpoint. On diabetes, one product being moved to in-house production is preparing for Phase 1 clinical trials after formulation work.

On March 6, 2026, the board resolved to cancel 2,459 treasury shares, with cancellation scheduled for April 10, 2026, and the company framed it as a step to enhance shareholder value. When contract manufacturing for long-acting injectables starts to show up in revenue has not been disclosed and needs to be tracked.

The 2026 annual report will show confirmed full-year revenue and operating margin, along with whether tablet sales recover after production resumed.

07

Valuation

PER
11.9×
PBR
0.8×
ROE
7.0%
EPS
₩537
BPS
₩7,963
Dividend per share
₩0

The share price is below book value per share, meaning it trades without a premium over net assets. All KRW 98 billion of total equity at the end of 2025 belongs to controlling shareholders, so no non-controlling interest adjustment is needed.

On earnings, attributable net income for the last four quarters totals KRW 7.09 billion. Because that total mixes a fourth-quarter 2025 net loss with a first-quarter 2026 profit, the multiple on a single-quarter basis carries a wide range of interpretation.

On an annual basis, attributable net income peaked in 2023 and was KRW 4.97 billion in 2025. The dividend yield is below the sector average, and treasury share cancellation is the main shareholder return action on record.

Set against an operating margin that fell from 9.9% in 2023 to 5.3% in 2025, the same net asset base corresponds to a different earnings capacity. The share price has moved sharply within short periods on policy themes and trading flows, so the same earnings can correspond to different multiple levels.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Sustained revenue growth

Revenue rose for three consecutive years from 2023 through 2025 to KRW 106.4 billion. It has also increased for three straight quarters through the third quarter of 2026, when sales reached KRW 30.9 billion, up 13.3% year on year. The company attributes this to seasonal antibiotic products and wider distribution through CSO partners.

Improved new drug commercialization

A hypertension improved new drug in combination form received approval in February 2026 and launched in July. It is one of the pipeline items that has reached the market. A diabetes product being moved to in-house production is also preparing for Phase 1 clinical trials after formulation work.

Long-acting injectable production base

A plant built in Anseong with about KRW 27.0 billion of investment in 2023 is described as a dedicated facility for long-acting injectables. Press reports say Chong Kun Dang and Daewoong Pharmaceutical, both developing hair-loss treatments, chose the company as a production partner. The company presents contract manufacturing of long-acting hair-loss injectables as its next growth axis.

09

Bear factors

Falling operating margin

Operating margin fell from 9.9% in 2023 to 5.5% in 2024 and 5.3% in 2025. Revenue in 2025 was about KRW 3.7 billion higher than in 2024, yet operating profit stayed at KRW 5.66 billion, flat year on year. Revenue growth has not translated into margin recovery.

Quarterly earnings volatility

Operating profit fell to KRW 244 million in the first quarter of 2026, down 82.3% quarter on quarter. The fourth quarter of 2025 turned to an attributable net loss of KRW 120 million. Attributable net income in the third quarter of 2026 was KRW 1.27 billion, down 40.8% year on year.

Production halt and pipeline setbacks

Tablet manufacturing was suspended for one month from January 2026, and production resumed on February 20. Two diabetes improved new drug candidates were stopped before clinical entry, with the company citing changes in the market environment. Results across improved new drugs have been uneven by therapeutic area.

10

Risk factors

Production and regulatory risk

As the tablet suspension showed, administrative actions can directly disrupt production and revenue. When sales are concentrated in one dosage form, inventory levels determine how much a production halt hurts. Changes in drug pricing policy are also a variable for profitability in a generic-focused business.

Pipeline risk

Two improved new drug candidates were stopped before clinical entry. The company cited market environment changes and has said there are no plans to resume. New businesses such as long-acting hair-loss injectables could face delays in trials and approvals, leaving the timing of their earnings contribution uncertain.

Share price volatility

In August 2026 the company disclosed designation as a short-term trading caution stock due to concentrated trading in a small number of accounts, with a 3-day price change of 18.58%. Under the exchange's rules, the designation can be escalated to warning or risk stages. The share price has been sensitive to theme-driven trading, so non-earnings factors play a large role.

11

What to watch next

  1. January–February 2027 (typical timing)

    Check whether preliminary full-year 2026 results are disclosed. Whether operating margin holds near the 5.3% level of 2025 is the key test.

  2. By March 31, 2027

    Confirm the 2026 annual report filing within the statutory deadline. It will show fourth-quarter 2026 results, confirmed full-year revenue and operating profit, and whether tablet sales recovered after production resumed.

  3. Around May 15, 2027

    Review the first-quarter 2027 quarterly report. Check the quarterly profit trend after the first-quarter 2026 operating low of KRW 244 million, and the non-operating items behind attributable net income that ran well above operating profit.

  4. Timing undetermined

    Track whether discussions on insurance reimbursement for hair-loss drugs resume, and any disclosure of clinical or approval progress for long-acting hair-loss injectables. Also watch how policy headlines affect the share price apart from earnings.

12

Overall view

Withus Pharmaceutical grew revenue from KRW 64.7 billion in 2022 to KRW 106.4 billion in 2025, and quarterly revenue has risen for three straight quarters through the third quarter of 2026. Profit has not kept pace with sales, however.

Operating margin fell from 9.9% in 2023 to 5.3% in 2025, and first-quarter 2026 operating profit dropped to KRW 244 million. Attributable net income declined in both the second and third quarters of 2026, and the last four quarters total KRW 7.09 billion.

Strengths include continued revenue growth, the launch of a hypertension improved new drug, and the Anseong injectable plant with its contract manufacturing potential.

Weaknesses include a low operating margin, quarterly earnings volatility, the impact of the January 2026 production halt, and the discontinuation of diabetes candidates. The weight of these two sets of factors can be checked against confirmed figures in the 2026 annual report.

The checkpoints are whether operating margin recovers, how tablet sales trend after production resumed, and when long-acting injectable operations show up in revenue.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. jobkorea.co.kr
  2. m.dailypharm.com
  3. m.dailypharm.com
  4. hkn24.com
  5. m.dailypharm.com
  6. vegannews.co.kr
  7. dailypharm.com
  8. finance.eduinfom.com
  9. saramin.co.kr
  10. ksdaily.co.kr
  11. m.news.nate.com
  12. m.news.nate.com
  13. topstarnews.net
  14. medicopharma.co.kr
  15. cbci.co.kr
  16. m.news.nate.com
  17. m.irgo.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis